Title Image

Press Release | Dynamic42 develops new generation of biotech chips for organ-on-chip technology

cross section model biotech chip BC003

Press Release | Dynamic42 develops new generation of biotech chips for organ-on-chip technology

Jena – Dynamic42 GmbH started the production of a new generation of innovative biotech chips for the organ-on-chip technology. With this chip, developed in-house, the effect of chemical substances can be examined directly on human organ replicas.

In addition, complex models relating to immunological issues can be mapped, which are used in basic research and drug development. The novel chip BC003 was successfully tested in a pilot project in cooperation with the working group of Prof. Nicole Teusch from the Heinrich Heine University Düsseldorf. In this project, a cancer model was developed from pancreatic cells to investigate therapeutic options.

cross section model biotech chip BC003

Cross-section model BC003

Dynamic42 GmbH

Replication of complex tissue cultures in the BC003 chip

The special feature of the new chip is the spatial design with three culture chambers. This enables the cultivation of complex, three-dimensional tissue cultures. Until now, many organ-on-chip applications have used chips with two very narrow chambers on top of each other. However, this quickly leads to limitations in terms of spatial dimensions. The technical integration of spheroids (spherical tissue structures) in chip formats with a simultaneously flowing culture medium has been difficult to design up to now. Applications such as biologically complex tumour models in chip applications remained limited.


“The chip allows us to dive into completely new application areas for organ-on-chip technology, such as cancer research,” explains Dr. Martin Raasch, CEO of Dynamic42. “To improve the significance of research results that are transferable to the human organism, we have designed the chip architecture to be more complex. The main advantage for the user is that this does not complicate handling.”

Expanding the application areas of organ-on-chip technology

Multi-layered, artificially created and self-organising tissues, so-called organoids, could hardly be satisfactorily reconciled in a meaningful combination with microfluidics so far. The same applies to the very popular technique of spheroid culture. The novel chips open up the possibility of cultivating spheroids and stem cell-based organoids in one chip platform and combining them with other tissue components, such as blood vessel tissue.


“With an additional chamber and integrated microcavities, so to speak small recesses for the tissue spheroids, we have created an innovative chip design here and are also bridging the gap between our technology and the rapidly emerging stem cell technology,” adds Dr Martin Raasch.


In the current investigation of pancreatic cancer tissue on the three-chamber chip BC03, tissue spheroids of the pancreas are microfluidically cultivated together with blood vessel tissue on the chip and tested for drug trials. This internal test phase will be completed in spring 2023. The results so far have been so satisfactory that the chip has already been offered since the first quarter.

How the mini-labs on biotech chips work

For the organ-on-chip procedure, cells of human organs are grown in the channels of a biotech chip on a membrane. They are supplied with nutrients and biomechanically stimulated by an artificial blood flow. This significantly increases the functionality of the tissue and the results become meaningful in relation to humans. Depending on the object of investigation, active substances, e.g. from new drugs under development, can be added to the biotech chip. The reactions of the cells to the additional active substances can be evaluated under the microscope, among other things.

Alternative to animal testing

Organ-on-a-chip technology is a veritable alternative to animal testing. By replicating human organ functions and using them for tests, the corresponding analyses on laboratory animals are reduced.

Information about Dynamic42

Dynamic42 is a contract company in the rapidly developing organ-on-a-chip market, founded in 2018 as an offshoot of Jena University Hospital. With its organ-on-a-chip platform, the start-up develops in vitro test systems that can be used to investigate the effect of potential drug substances and chemicals on the human organism. The company also produces its own biotech chips that significantly improve the quality and informative value of the organ-on-a-chip process.

PR Management Nancy Blaurock-Möller

Media Contact:

Dr. Nancy Blaurock-Möller

PR Management

Dynamic 42 GmbH

Winzerlaer Straße 2

07745 Jena

Phone +49 3641 508101


Read more News:

Joanna Nowacka joins Dynamic42 as Lead for Stem Cell Model Development

We are delighted to announce that Joanna Nowacka has joined Dynamic42 as Lead for Stem Cell Model Development.

Press Release | Biotech company Dynamic42 launches open platform for organ model development

Dynamic42 has launched the “DynamicOrgan System”, an open, flexible, and cost-effective organ-on-chip platform for lab use.

Mari Kakihara joins Dynamic42 to support Finance and Controlling

We are excited to announce that Mari Kakihara has joined us recently to support Finance and Controlling.